Clinical Report: 2025 ESMO Prostate Cancer Highlights
Overview
The ESMO 2025 conference presented significant findings on prostate cancer, particularly regarding the role of enzalutamide in high-risk localized disease. The study results indicate that while enzalutamide did not improve metastasis-free survival overall, it showed benefits in specific patient subgroups.
Background
Prostate cancer remains a leading cause of cancer-related morbidity and mortality. Recent advancements in treatment strategies, particularly in localized and metastatic disease, emphasize the importance of precision medicine. Understanding the efficacy of therapies like enzalutamide in various patient populations is crucial for optimizing treatment outcomes.
Data Highlights
No numerical data available in the provided source.
Key Findings
- Enzalutamide did not improve metastasis-free survival (MFS) in high-risk localized prostate cancer overall.
- Patients with node-positive disease showed improved MFS with enzalutamide (hazard ratio 0.43).
- PSA progression-free survival was improved in the enzalutamide group (hazard ratio 0.78).
- Prostate cancer-specific survival remained high at 96-97% with ADT plus radiation.
- Higher rates of fatigue and nervous system events were observed in the enzalutamide arm.
- Future studies are needed to identify biomarkers for selecting patients who may benefit from intensified therapy.
Clinical Implications
Clinicians should consider the specific characteristics of high-risk localized prostate cancer patients when deciding on the addition of enzalutamide to standard therapy. The findings suggest that not all patients may require intensification, highlighting the need for personalized treatment approaches.
Conclusion
The ESMO 2025 findings underscore the complexity of treatment decisions in prostate cancer, particularly regarding the use of enzalutamide. Ongoing research is essential to refine patient selection and improve outcomes.
References
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 2025 -- 2025 ESMO Bladder Cancer Highlights
- The ASCO Post, 2019 -- ESMO Congress 2019: Quick Takes From Key Clinical Trials
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 2025 -- Prostate Cancer Conference Highlights from ASCO GU 2025
- EAU Guidelines, 2026 -- Guidelines on Prostate Cancer
- PubMed, 2023 -- Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
- dana-farber — 2025 ESMO Kidney Cancer Highlights
- https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2026_2026-03-14-104356_ixav.pdf
- Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
